Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (10992)	11/12/1997 2:33:00 AM
From: squetch	Respond to of 32384

Even worse the overnight US bond was actually down three ticks at 1am cst.

To: Andrew H who wrote (10992)	11/12/1997 2:41:00 AM
From: squetch	Read Replies (1) \| Respond to of 32384

Here is some info from a Rezulin ad I saw. This is from the fine print part and I don't know if this "caution" section was pre or post FDA letter. During all clinical studies in NorthAmer (n=2510) a total of 20 Rez-treated patients were withdrawn for treatment b/c of liver fx test abnormalities. 2/20 developed reversible jaundice. Both had biopsies which were consistent w/ idiosyncratic drug reaction. In premenopousal anormulatroy patients w/ insulin resistance, Rez may result in resumption of ovulation. hemogloblin decreased 3-4% compared w/ a 1-2% decrease in placebo. Change occured in first 4-8 weeks. Levels stabilized and remained unchanged(up to two years in my recollection is correct Yes a big IF) Risk of hypoglycemia if used in combo w/ insulin or oral hypoglycemic agents Recomend insulin not Rez during pregnancy.